Proteina Co.,Ltd. develops protein-protein interaction profiling technology. The company offers technology that confirms the real-time activation of cancer signal pathways by directly seeing the relevant proteins, predicts the efficacy of drugs, and enables doctors to select which inhibitor to prescribe by confirming which bypass signal pathways are inducing resistance. It also offers single molecule protein interaction detection platform to analyze protein and protein-protein interaction (PPI) information. Proteina Co., Ltd. was founded in 2015 and is based in Seoul, South Korea.